rs1801275 — IL4R Q576R

Gain-of-function missense variant in the IL-4 receptor alpha chain that amplifies Th2 immune signaling, increasing susceptibility to asthma, atopic dermatitis, and allergic disease

See your personal result for IL4R

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

IL-4 Receptor Q576R — The Allergy Amplifier

The IL4R gene11 IL4R gene
Interleukin-4 receptor alpha, located at chromosome 16p12.1 encodes the alpha chain of the interleukin-4 receptor, a critical gatekeeper in the immune system's decision to mount allergic-type (Th2) responses. The Q576R variant (rs1801275) is a single nucleotide change (A>G) that replaces glutamine with arginine at position 576 in the intracellular signaling domain. This is not a subtle tweak — it creates a gain-of-function receptor22 gain-of-function receptor
A gain-of-function mutation increases a protein's activity beyond its normal level, rather than reducing or eliminating it that amplifies downstream immune signaling, pushing the immune system toward allergic and inflammatory responses.

The G allele is remarkably common, carried by about 20% of Europeans and up to 69% of individuals of African descent. Despite being classified as benign by ClinVar (it does not cause a discrete genetic disease), the variant has robust associations with asthma severity, atopic dermatitis, elevated IgE levels, and food allergy risk.

The Mechanism

IL-4Rα forms part of two receptor complexes: the type I receptor33 type I receptor
IL-4Rα paired with the common gamma chain (γc), used primarily by immune cells (with γc) and the type II receptor (with IL-13Rα1). When IL-4 or IL-13 binds, intracellular JAK kinases phosphorylate the receptor, normally activating STAT6 to drive Th2 differentiation, IgE class switching, and mucus production.

The R576 substitution introduces a critical structural change. The arginine at position 576 renders the adjacent tyrosine at Y575 into a consensus binding site for the adaptor protein GRB244 GRB2
Growth factor receptor-bound protein 2, an adaptor that links receptor tyrosine kinases to downstream signaling cascades. When Y575 is phosphorylated by JAKs, GRB2 docks onto the receptor and activates the ERK1/2 MAP kinase cascade55 ERK1/2 MAP kinase cascade
Extracellular signal-regulated kinases, part of the mitogen-activated protein kinase pathway that regulates cell growth and differentiation. This drives autocrine IL-6 production, which in turn activates STAT3 — a transcription factor not normally engaged by the wild-type receptor. The result is dual STAT6 and STAT3 activation, promoting a mixed Th2/Th17 inflammatory profile associated with more severe allergic disease and steroid-resistant airway inflammation66 steroid-resistant airway inflammation
Inflammation that does not respond adequately to corticosteroid treatment, a hallmark of severe asthma.

Critically, the R576 variant also destabilizes regulatory T cells (Tregs). Induced Tregs expressing R576 show decreased methylation at the Foxp3 CNS2 locus77 Induced Tregs expressing R576 show decreased methylation at the Foxp3 CNS2 locus
This epigenetic change makes Tregs unstable and prone to converting into pro-inflammatory Th17 cells, causing them to lose their suppressive function and acquire a Th17-like phenotype. This Treg-to-Th17 conversion further amplifies the inflammatory response.

The Evidence

Clinical evidence for Q576R spans asthma, atopic dermatitis, and food allergy.

A meta-analysis of 7 studies (912 cases, 708 controls)88 meta-analysis of 7 studies (912 cases, 708 controls)
All studies from Chinese pediatric populations using PCR-RFLP methodology found the G allele significantly increases pediatric asthma risk across all genetic models: GG versus AA showed OR 3.75 (95% CI 1.89-7.45), AG versus AA showed OR 2.15 (95% CI 1.36-3.39), and the dominant model yielded OR 2.25 (95% CI 1.42-3.57). In a Saudi Arabian population study99 Saudi Arabian population study
190 asthmatic and 194 controls, the G allele conferred OR 2.12 (95% CI 1.39-3.22) for asthma susceptibility.

For atopic dermatitis, the evidence emphasizes disease severity rather than susceptibility. In the ADRN cohort of 1,116 Caucasian AD patients1010 ADRN cohort of 1,116 Caucasian AD patients
Atopic Dermatitis Research Network, a large prospective cohort, R576 carriers had significantly higher Rajka-Langeland severity scores (p=0.02-0.037). A Vietnamese population study of 113 AD patients and 213 controls1111 Vietnamese population study of 113 AD patients and 213 controls found the G allele associated with higher SCORAD severity scores in the dominant model (OR 4.67, p=0.005), with a clear dose-response: median SCORAD scores of 30.5 (AA), 39 (AG), and 49.65 (GG).

Mouse models confirm the gain-of-function mechanism: IL4raR576 mice showed robust lung eosinophilia with neutrophilia1212 IL4raR576 mice showed robust lung eosinophilia with neutrophilia
Indicating mixed Th2/Th17 inflammation not seen with the wild-type receptor, exaggerated airway hyperresponsiveness, elevated OVA-specific IgE/IgG1, and increased IL-13 secretion by splenocytes compared to wild-type controls.

The variant also mediates food allergy risk through atopic dermatitis. Each risk allele increases odds of AD 1.39-fold, and AD increases odds of food allergy 2.68-fold for severe food allergy symptoms1313 Each risk allele increases odds of AD 1.39-fold, and AD increases odds of food allergy 2.68-fold for severe food allergy symptoms
Supporting the dual-allergen hypothesis that epicutaneous sensitization through damaged skin barrier drives food allergy, demonstrating that Q576R contributes to the atopic march from eczema to food allergy.

Practical Actions

The core challenge for G allele carriers is an immune system biased toward Th2/allergic responses, with impaired Treg function and a tendency toward steroid-resistant inflammation. Interventions should target this specific imbalance.

Quercetin directly counteracts the IL-4/STAT6 axis. In vitro studies show quercetin at concentrations of 5 micromolar or higher suppresses IL-4-induced STAT6 phosphorylation and Th2 cytokine production1414 In vitro studies show quercetin at concentrations of 5 micromolar or higher suppresses IL-4-induced STAT6 phosphorylation and Th2 cytokine production
Peak plasma levels after 1,200 mg oral dose reach approximately 12 micromolar, exceeding the effective in vitro threshold, suppressing IL-5 and IL-13 while restoring IFN-gamma production.

Vitamin D modulates the Th1/Th2 axis. Supplementation with vitamin D3 normalizes Th1 and Th2 interleukin patterns and reduces atopic dermatitis severity1515 Supplementation with vitamin D3 normalizes Th1 and Th2 interleukin patterns and reduces atopic dermatitis severity
1,000 IU daily for 3 months significantly reduced SCORAD scores in children with AD, directly relevant to the Th2 polarization driven by this variant.

Total serum IgE measurement quantifies the downstream consequence of enhanced IL-4R signaling and tracks whether interventions are working. Specific IgE panels identify the allergens most affected by your amplified Th2 response.

Interactions

The Q576R variant interacts with two other IL4R polymorphisms: [I75V (rs1805010) | Ile75Val, located in the extracellular domain, also associated with atopy and IgE regulation] and S503P (rs1805015). These three variants form haplotypes with compounded effects on IL-4 signaling. Multiple risk alleles across these loci may additively increase atopic disease susceptibility.

Given IL-4Rα's role in both type I (IL-4) and type II (IL-4/IL-13) receptor complexes, this variant interacts functionally with IL-13 pathway variants. The combined effect of enhanced IL-4R signaling with variations in IL-13 itself could substantially amplify Th2-driven inflammation beyond what either variant produces alone.

The Q576R variant is particularly relevant to dupilumab pharmacology. Dupilumab, a monoclonal antibody blocking IL-4Rα, directly targets the receptor this variant modifies. Carriers of the gain-of-function R576 allele may represent a population with particularly enhanced IL-4R signaling who could benefit most from this targeted blockade, though pharmacogenomic studies specifically linking Q576R genotype to dupilumab response are still emerging.

Genotype Interpretations

What each possible genotype means for this variant.

AA Standard Signaling Normal

Normal IL-4 receptor function with standard Th2 immune responses

You have two copies of the ancestral A allele, encoding glutamine at position 576 of your IL-4 receptor alpha chain. Your IL-4R signals through the standard STAT6 pathway without the additional GRB2-ERK-STAT3 cascade that the variant creates. About 42% of people globally share this genotype, though frequency varies significantly by ancestry — this is the majority genotype in European (about 64%) and East Asian (about 69%) populations.

AG Enhanced Signaling Intermediate

One copy of the gain-of-function IL-4R variant — moderately amplified Th2 immune response

The heterozygous state produces a mixture of wild-type and variant IL-4 receptors on your immune cells. When IL-4 binds to the variant receptors, the R576 substitution allows GRB2 recruitment to phosphorylated Y575, activating ERK1/2 and driving autocrine IL-6 production. This IL-6 activates STAT3, promoting a mixed Th2/Th17 inflammatory profile. However, since approximately half your receptors function normally, the net effect is intermediate.

Clinical data from large cohorts show heterozygous carriers have measurably higher atopic disease severity scores than AA homozygotes, though the effect is less pronounced than in GG carriers. The Treg destabilization effect — reduced Foxp3 CNS2 methylation leading to Th17 conversion — also occurs but to a moderate degree.

GG Amplified Signaling High

Two copies of the gain-of-function IL-4R variant — strongly amplified Th2 immune response with Treg instability

With both alleles encoding R576, every IL-4 receptor on your immune cells signals through both the canonical STAT6 pathway and the aberrant GRB2-ERK-IL-6-STAT3 pathway. This dual activation creates a mixed Th2/Th17 inflammatory state that is notably more difficult to treat with corticosteroids. Mouse models of the homozygous R576 genotype show robust lung eosinophilia accompanied by neutrophilia, dramatically elevated OVA-specific IgE, and exaggerated airway hyperresponsiveness.

The Treg instability is most severe in the homozygous state. Reduced Foxp3 CNS2 methylation causes induced Tregs to lose suppressive function and acquire IL-17 and RORgammat expression, effectively converting them into pro-inflammatory Th17 cells. This undermines immune tolerance and may explain why GG carriers are more likely to develop steroid-resistant inflammation.

In the Vietnamese population study, GG carriers had a median SCORAD score of 49.65, compared to 39 for AG and 30.5 for AA, demonstrating a clear gene-dose effect on atopic dermatitis severity.